All news

Boston Trust Walden sells 92.9% of Amdocs stake

Alpha Vantage · MarketBeat · · AI-summarised by FinFlash

Boston Trust Walden Corp cut its Amdocs Limited stake by 92.9% in the third quarter, while other institutional investors adjusted their holdings. Amdocs reported quarterly earnings and revenue in line with analyst estimates and declared a dividend of $0.569 per share. Analysts rate the stock a Hold with an average price target of $78.33, suggesting limited near-term conviction for investors.

Read original source

DOX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.